Richard Kuntz
Known title: SVP & Chief Medical & ScienceCIK: 0001341125
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
MiniMed completes separation from Medtronic. Medtronic has finalized the separation of its MiniMed insulin pump business, which is now operating as an independent company with a new board of directors. This corporate restructuring marks a significant shift in Medtronic's portfolio structure. Meanwhile, the company was named to the TIME Best Inventions of 2026 list for its Stealth AXiS surgical system and Corsano wearable, highlighting continued innovation in its remaining product lines.
Transaction History
| INVE | ▲ Buy | Grant | 17,544 | $0 | 7/30/2026 | View on chart |
| INVE | ▲ Buy | Grant | 21,148 | $0 | 7/29/2025 | View on chart |
| DMAC | ▲ Buy | Grant | 9,925 | $53K | 1/2/2025 | View on chart |
| INVE | ▲ Buy | Grant | 14,773 | $0 | 7/29/2024 | View on chart |
| DMAC | ▲ Buy | Grant | 14,285 | $40K | 1/2/2024 | View on chart |
| INVE | ▲ Buy | Grant | 8,904 | $0 | 8/1/2023 | View on chart |
| INVE | ▲ Buy | Grant | 3,343 | $0 | 10/31/2022 | View on chart |
| MDT | ▼ Sell | Tax Withholding | 209 | $26K | 11/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction
DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.
DiaMedica Shares Early Phase 2 Data for DM199 in Fetal Growth Restriction. DiaMedica Therapeutics is highlighting early Phase 2 results for its lead candidate, DM199, which targets fetal growth restriction. The company is using a webinar with key opinion leaders to discuss these findings, signaling a focus on advancing its clinical narrative. This update provides new information on the drug's potential efficacy as it moves through its development stages.